有市场人士对第一财经记者表示，次新股、盘子小，再加上近期刚刚被纳入港股通，这些因素综合在一 起，促使药捷安康股价被爆炒，但公司基本面是否有足够的支撑，值得商榷。 今日午间，药捷安康也发布了股价及成交量的异常变动自愿性公告称，董事会确认，概不知悉导致股份 出现该等股价及成交量异常变动之任何原因，或任何须予公布以避免股份出现虚假市场之资料，或须予 披露之任何内幕消息。 （文章来源：第一财经） 在经历了四个交易日连续暴涨后，今日，药捷安康（02617.HK）股价上演了一场"高台跳水"行情。 今日早盘，该公司股价最大涨幅超过60%，冲到670港元/股以上；午后开盘后，股价又一路滑落，最后 以暴跌53.73%收盘，股价仅剩下192港元/股，市值跌回千亿港元以下，为762.04亿港元。 药捷安康于2025年6月23日才在港股市场挂牌交易，彼时公司IPO首发价只有13.15港元/股，公司当前股 价较首发价涨幅仍高达13.6倍。上一交易日，即9月15日，公司收盘价曾高达415港元/股，股价较IPO首 发价涨幅约30.6倍，总市值达到1647.13亿港元。 药捷安康是一家处于注册临床阶段的创新药公司，专注于发现及开发肿瘤、炎症 ...

公司市值跌回千亿港元以下。 在经历了四个交易日连续暴涨后，今日，药捷安康（02617.HK）股价上演了一场"高台跳水"行情。 今日早盘，该公司股价最大涨幅超过60%，冲到670港元/股以上；午后开盘后，股价又一路滑落，最后 以暴跌53.73%收盘，股价仅剩下192港元/股，市值跌回千亿港元以下，为762.04亿港元。 药捷安康于2025年6月23日才在港股市场挂牌交易，彼时公司IPO首发价只有13.15港元/股，公司当前股 价较首发价涨幅仍高达13.6倍。上一交易日，即9月15日，公司收盘价曾高达415港元/股，股价较IPO首 发价涨幅约30.6倍，总市值达到1647.13亿港元。 药捷安康是一家处于注册临床阶段的创新药公司，专注于发现及开发肿瘤、炎症及心脏代谢疾病小分子 创新疗法。截至2025年6月30日，公司主要管线包括六款临床阶段候选产品及多款临床前阶段候选产 品。替恩戈替尼是药捷安康研发进度最快的产品，同时也是公司的核心产品，这是一款选择性聚焦多激 酶抑制剂，主要靶向三个关键通路——FGFR/VEGFR、JAK和Aurora激酶，但进度最快的适应证为胆管 癌，为小癌肿，公司预计在中国的注册性2期临床于 ...

Core Viewpoint - The stock price of药捷安康-B (02617.HK) experienced extreme volatility today, with an initial surge of over 60% followed by a sharp decline, highlighting the unpredictable nature of the market and investor sentiment [1][2][4]. Group 1: Stock Price Movement - In the morning, the stock price peaked at 679.5 HKD per share, bringing the market capitalization close to 270 billion HKD [1][2]. - After an announcement regarding unusual trading activity, the stock price plummeted to a low of 165 HKD per share, resulting in a decline of over 60% [2][4]. - By the end of the trading day, the stock closed at 192 HKD per share, reflecting a decrease of 53.73% and a market capitalization of 76.2 billion HKD [2]. Group 2: Company Announcements - The company issued a statement confirming that it was unaware of the reasons behind the stock price and trading volume fluctuations, asserting that its business operations and financial status remained stable [4]. - The board of directors indicated that there were no significant changes in the company's operations or financial conditions that warranted disclosure [4]. Group 3: Recent Performance and Developments -药捷安康's stock has seen a dramatic increase since its listing on June 23, with a rise of over 500% from September 10 to September 15 [6]. - The company’s core product, Tinengotinib, received clinical trial approval for treating specific types of breast cancer, contributing to the stock's previous surge [5][6]. - Despite the stock's volatility, the company remains in a loss-making position, with a reported pre-tax loss of 123 million HKD for the first half of the year, an improvement from the previous year's loss of 160 million HKD [7].

Company Overview - Yaojie Ankang-B (02617.HK) is a clinical-stage biopharmaceutical company focused on discovering and developing innovative small molecule therapies for oncology, inflammation, and cardiovascular metabolic diseases [4]. Stock Performance - On September 16, Yaojie Ankang-B experienced extreme volatility, with an initial surge of over 63%, reaching a peak price of 679.50 HKD, which is more than 50 times its issue price [2]. - The stock price plummeted dramatically after 14:11, falling to around 280 HKD within an hour, and eventually closing at 192 HKD, marking a decline of 53.73% for the day [2]. - The trading volume was significant, with a total turnover of 45.4 billion HKD and a turnover rate of 4.13% [2]. Financial Status - Yaojie Ankang-B reported zero revenue for the first half of the year and incurred a loss of 123 million HKD [4]. - The company's market capitalization briefly exceeded 250 billion HKD but fell to 76.2 billion HKD after the stock's decline [4]. Market Context - The broader Hong Kong stock market showed mixed performance on the same day, with the Hang Seng Index closing at 26,438.51 points, down 0.03%, while the Hang Seng Tech Index rose by 0.56% [4]. - Other pharmaceutical stocks, such as Fosen Pharmaceutical (01652.HK), saw significant gains, with a rise of over 350% following the approval of a new drug [6]. Capital Flow - After several days of net buying, southbound capital experienced a net sell-off of 3.189 billion HKD on the same day [8]. Market Outlook - Analysts from various firms suggest that the Hong Kong stock market may continue to rise due to ample liquidity and favorable valuation compared to global markets [10].

(本文来自第一财经) 药捷安康-B跳水，涨幅收窄至20%以内，早盘一度涨近60%，公司午间公告称概不知悉导致股份出现股 价及成交量异常变动的任何原因。 ...

Core Viewpoint - The stock price of药捷安康-B (02617.HK) experienced extreme volatility, with an initial surge of over 60% to a peak of 679.5 HKD per share, followed by a sharp decline of over 60% to a low of 165 HKD per share, resulting in a total intraday fluctuation exceeding 120% [1][2][4]. Group 1: Stock Performance - The stock reached a market capitalization close to 270 billion HKD before plummeting to below 70 billion HKD by the end of the trading day [1][2]. - The closing price was reported at 192 HKD per share, reflecting a decline of 53.73% from its earlier peak [2]. Group 2: Company Announcements -药捷安康 issued a statement acknowledging the unusual stock price and trading volume fluctuations, confirming no significant changes in its business operations or financial status [4]. - The board of directors stated they were unaware of any reasons for the stock price movements or any information that should be disclosed to prevent a false market [4]. Group 3: Company Background and Financials -药捷安康 went public on June 23, with an initial offering price of 13.15 HKD per share, and has seen its stock price increase significantly since then, with a reported increase of 5067% from the IPO price [5][6]. - The company remains in a loss-making position, with a pre-tax loss of 123 million HKD for the first half of the year, an improvement from a loss of 160 million HKD in the same period the previous year [7]. - Other income and revenue dropped by 65.1% to 3.6 million HKD, primarily due to reduced bank interest and government subsidies [7].

Core Viewpoint - The stock of Yaojie Ankang (02617.HK) experienced significant volatility, closing at 192 HKD with a decline of 53.73%, after reaching a peak of 679.5 HKD, which represented an increase of 63.73% during the trading session [1] Company Overview - Yaojie Ankang is a biopharmaceutical company focused on discovering and developing innovative small molecule therapies for oncology, inflammation, and cardiovascular metabolic diseases, currently in the clinical registration phase [1] IPO Details - Yaojie Ankang was listed on the Hong Kong Stock Exchange on June 23, 2025, with a total of 15,281,000 H-shares offered. The final number of shares for public offering in Hong Kong was 3,057,000 H-shares, while the international offering accounted for 12,224,000 H-shares [1] - The final offering price was set at 13.15 HKD per share, raising a total of 200.95 million HKD. After deducting the estimated listing fees of 39.61 million HKD, the net proceeds amounted to 161.34 million HKD [1]

Core Viewpoint - The stock price of药捷安康-B (02617.HK) experienced significant volatility, dropping 45% after previously surging 63% to a peak of 679.5 HKD per share [1][3]. Company Overview -药捷安康 is a clinical-stage biopharmaceutical company focused on developing innovative small molecule therapies for oncology, inflammation, and cardiovascular metabolic diseases [3]. - The company has no commercialized products and reported zero revenue with a loss of 123 million HKD in the first half of the year [3]. Stock Performance - The stock price increased dramatically, with a cumulative rise of over 30 times since its IPO price of 13.15 HKD, reaching a market capitalization exceeding 120 billion HKD [3]. - The stock was recently included in the Hong Kong Stock Connect program, allowing southbound funds to invest in it [3]. Clinical Developments - On September 10, the company announced that its core product, Tinengotinib (TT-00420), received clinical approval from the National Medical Products Administration of China for a Phase II trial in treating HR+/HER2- metastatic breast cancer [3][4]. - Early clinical results indicated promising effects of Tinengotinib as a monotherapy in patients with HR+/HER2- breast cancer who have undergone multiple treatments [4]. Competitive Landscape - There are currently no other products in development with the same mechanism as Tinengotinib, although there are various competitors in related cancer treatment areas [7]. - The market for small molecule drugs is competitive, with larger biologics generally having greater potential [7]. Shareholding Structure - The founder, Wu Yongqian, holds a 32.98% stake in the company, contributing to a limited market float with only 15.281 million shares available for trading out of a total of 397 million shares [7]. - The stock exhibited a trading volatility of 131.09% with a low turnover rate of 4.74% as of September 12 [7]. Company History -药捷安康 has faced challenges in its journey to listing, having attempted to go public on three occasions in 2021, 2022, and 2024 [8]. - The company has a pipeline of six clinical-stage candidates and one preclinical candidate [8].

Group 1 - The stock price of药捷安康 (02617.HK) experienced significant volatility on September 16, with an intraday increase of over 60% followed by a decline of 53.73%, closing at 192 HKD per share and a total market capitalization of 762 billion HKD [1] - From September 11 to 15, the stock saw a cumulative increase of 361.11%, with a notable rise of 115.58% on September 15 [1] -药捷安康 is a biopharmaceutical company focused on developing innovative small molecule therapies for oncology, inflammation, and cardiovascular metabolic diseases, currently in the clinical registration phase [1] Group 2 - The company has not yet achieved commercialization, with projected losses of 343 million CNY and 275 million CNY for the years 2023 and 2024, respectively [2] - In the first half of the year, the company reported zero revenue and a loss of 123 million CNY [2] - On September 10, the company announced that its core product, Tinengotinib (TT-00420), received clinical approval for a Phase II trial for a specific type of breast cancer [1]

Core Viewpoint - The stock price of药捷安康 (02617.HK) has surged dramatically, reaching a market capitalization of over 240 billion HKD within three months of its IPO, despite the company not having any commercialized products and reporting a loss of 123 million HKD in the first half of the year [1][7]. Market Performance - As of September 16, the market capitalization of药捷安康 reached 249.3 billion HKD, surpassing established innovative pharmaceutical companies and approaching the market leader百济神州's valuation of 300 billion HKD [2]. - The stock price increased by nearly 600% over five trading days, with a peak price of 679.5 HKD on September 16 [1][6]. Investor Dynamics - The surge in stock price is attributed to significant inflows from southbound funds, which purchased over 300 million HKD worth of shares in two days [3]. - Key investors, including康方生物 and药石科技, have seen their investments yield over 50 times returns, with康方生物's shares valued at 517 million HKD compared to an initial investment of 10 million HKD [5][6]. Clinical Development - The stock's rise was triggered by the announcement of the clinical trial approval for its core product,替恩戈替尼, which targets multiple cancer pathways [3]. - As of June 30,替恩戈替尼 was involved in nine clinical trials globally, indicating a robust pipeline despite the company's current lack of revenue [3][7]. Financial Status - The company reported a net loss of 123 million HKD in the first half of the year, with research and development expenses of 98.43 million HKD and management expenses of 27.47 million HKD [7]. - As of June 30, the company held cash and cash equivalents of 449 million HKD, with total equity of 582 million HKD [7].